Glenn Saldanha

Pharmacist's listed Glenmark Pharmaceuticals, which he controls with his family, has been buffeted by currency depreciation and saw revenue from emerging markets (excluding India) decline 22%. The company derives 60% of its $1.2 billion in annual revenue from India and the U.S. Last year it received approvals to sell 19 generic drugs in the U.S., the most it has ever received in a year. Glenmark has 4 drugs in clinical trials, 2 of them in phase 2. Investors include Singapore's Temasek.